Both are critical to successful treatment, but how can optometrists help?

Catch up on what happened in optometry during the week of May 15-May 19.

Mitchell Jackson, MD, discussed laser scleral microporation from Ace Vision Group at the 2023 ASCRS annual meeting in San Diego.

Currently, there are several novel spectacle designs available across the world. Unfortunately, none of them are available in the US currently.

MIEBO, previously known as NOV03, is the first and only FDA-approved treatment for dry eye disease that targets tear evaporation.

John Berdahl, MD, discussed the Aurion clinical trials of endothelial cell therapy injection at the 2023 ASCRS annual meeting in San Diego.

Today, Alimera Sciences announced that they have acquired the US commercial rights of Yutiq (fluocinolone acetonide intravitreal insert) 0.18mg for the treatment of chronic non-infectious uveitis. Yutiq now joins Iluvien (fluocinolone acetonide intravitreal insert) 0.19 mg for DME in Alimera’s retina portfolio.

Comfortable technologies, easier fits, and attractive features enable patients older than 45 years to stay in contact lenses.

Lori Pacheco, RN, CRNO, discussed sports-related eye injuries and how to prevent them at the 2023 ASCRS annual meeting in San Diego.

Investigators reported “an increasing trend in the incidence of eye injuries associated with so-called ‘nonpowder’ guns among children.”

Anthony Wallace, Vice President and General Manager of the US Surgical Business at Bausch + Lomb, discussed the introduction of SeeLuma, a fully digital surgical visualization platform, and more at the 2023 ASCRS annual meeting in San Diego.

The organization now has chapters in Boston, San Antonio, New York, and Los Angeles.

Insights for eye care providers.

This medical device is the first retinal eye-movement monitor for non-invasive, objective clinical assessments.

Brian Shafer, MD, discussed Fortisite and the ability to treat corneal ulcers at the 2023 ASCRS annual meeting in San Diego.

It is important that clinicians are prepared with alternative methods for patients experiencing refractory CME after failed improvement with the agents that are most frequently used.

Catch up on what happened in optometry during the week of May 8-May 12.

Ophthalmology Times® spoke with Mitch Shultz, MD at ASCRS 2023 in San Diego where he shared insights from his presentation comparing patient results of the Hydrus stent and the iStent inject W with or without ABiC (or ab-interno canaloplasty).

Ocular trauma is a leading cause of monocular blindness in the US and is the second most common reason for eye-related hospitalizations

Lance Kugler, MD, recapped his presentation and findings on the safety of office space cataract surgery with the Ophthalmology Times© team at the ASCRS annual meeting in San Diego.